Seroprevalence of varicella zoster virus infection in child and adult population of Catalonia (Spain)

Medical Microbiology and Immunology

Volumn 197, Issue 3, 2008, Pages 329-333

  Salleras, Lluís ^a,d   Domínguez, Àngela ^a,d   Plans, Pere ^b,d   Costa, Josep ^c   Cardeñosa, Neus ^b,d   Torner, Núria ^b,d   Plasència, Antoni ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Directorate of Public Health   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Seroprevalence; Varicella zoster virus

Indexed keywords

CHICKENPOX VACCINE; IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES ZOSTER; HUMAN; IMMUNITY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RECOMMENDED DRUG DOSE; SEROPREVALENCE; SPAIN; VACCINATION; VARICELLA ZOSTER VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHICKENPOX; CHILD; CHILD, PRESCHOOL; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SPAIN;

EID: 44549083366     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-007-0064-z     Document Type: Article

References (31)

1. Heininger U, Seward JF (2006) Varicella. Lancet 368:1365-1375
2. Salleras L, Pujals JM, Salleras M (2003) Vacuna antivarizela-zoster. In: Salleras L (eds) Vacunaciones preventivas, 2nd edn. Masson, Barcelona, pp 311-330
3. Sauerbrei A, Wutzler P (2007) Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 2: Varicella-zoster virus infections. Med Microbiol Immunol 196:95-102
4. Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clinical Microbiol Rev 18:70-80
5. Armitage P, Berry G, Matthews JNS (2002) Statistical methods in medical research, 4th edn. Blackwell Science Limited, London
6. Office of Population Census and Surveys (1980) Classification of occupations. Office of Population Census, London
7. Demmeler GJ, Steinberg SP, Blum G, Gershon AA (1988) A rapid enzyme-linked immunosorbent assay for detecting antibodies to varicella-zoster virus. J Infect Dis 157:211-212
8. Salleras L, Domínguez A, Vidal J, Plans P, Salleras M, Taberner JL (2001) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19:183-188
9. Wharton M (1996) The epidemiology of varicella-zoster virus infection. Infect Dis Clin North Am 10:571-581
10. Ooi PL, Goh KT, Doraisingham S, Ling AE (1992) Prevalence of varicella-zoster virus infection in Singapore. Southeast Asian J Trop Med Public Health 23:22-25
11. Pachón I, Amela C, de Ory F, León P, Alonso M (1998) Encuesta nacional de seroprevalencia de enfermedades inmunoprevenibles. Año 1996. Bol Epidemiol Semanal 6:93-104
12. Gil A, González A, Dal-Ré R, Ortega P, Domínguez V (1998) Prevalence of antibodies against varicella zoster, Herpes simples (Types 1 and 2), hepatitis B and hepatitis A virases among Spanish adolescents. J Infect 36:53-6
13. Díez-Domingo J, Gil A, San-Martín M et al (2005) Seroprevalence of varicella among children and adolescents in Valencia, Spain: reliability of the parent's reported history and the medical file for identification of potential candidates for vaccination. Hum Vaccin 1:204-206
14. Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19:3097-3103
15. Svahn A, Bergren J, Parke A, Storsaeter J, Thorstensson R, Linde A (2006) Changes in seroprevalence to four herpesvirus over 30 years in Swedish children aged 9-12 years. J Clin Virol 37:118-123
16. Koskiniemi M, Lappalainen M, Schmid DS, Rubtcova E, Loparev VN (2007) Genotypic analysis of varicella-zoster virus and its seroprevalence in Finland. Clin Vaccine Immunol 14:1057-1061
17. Wutzler P, Färber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20:1214124
18. Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV et al (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161:588-593
19. Mossong J, Putz L, Schneider F (2004) Seroprevalence and force of infection of varicella-zoster virus in Luxembourg. Epidemiol Infect 132:1121
20. de Melker H, Berbers G, Hahne S et al (2006) The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 24:3946-3952
21. Khoshnood B, Debruyne M, Lançon F et al (2006) Seroprevalence of varicella in the French population. Pediatr Infect Dis J 25:41-44
22. Gabuti G, Penna C, Rossi MA et al (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126:433-440
23. Gürgöze MK, YIlmaz E, Gödekmerdan A, Akça Z, Doǧan Y, Akarsu S, Denizmen Aygün A (2006) Seroprevalence of mumps, varicella and rubella antibodies in children 1-16 years of age in eastern Turkey. Turk J Pediatr 48:185-188
24. Kurugol Z, Koturoglu G, Aksit S, Ozacar T (2007) Varicella seroprevalence in Turkish population in Cyprus. Acta Paediatr 96:861-863
25. Breuer J (2004) Varicella zoster virus. In: Zuckerman AJ, Banatvala JE, Pattison JR, Griffiths PD, Schoub BD (eds) Principles and practice of clinical virology, 5th edn. Wiley, Chichester, pp 53-83
26. Cohen DI, Davidovici BB, Smetana Z, Balicer RD, Klement E, Mendelson E, Green MS (2006) Seroepidemiology of varicella zoster in Israel prior to large-scale use of varicella vaccines. Infection 34:208-213
27. Nardone A, de Ory F, Carton M, Cohen D, van Damme P, Davidkin I et al (2007) The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 25:7866-7872
28. Borras E, Domínguez A, Batalla J, Torner N, Cardeñosa N, Nebot M, Plasencia A, Salleras L (2007) Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain). Vaccine 25:3240-3243
29. Smith WJ, Jackson LA, Watts DH, Koepsell TD (1998) Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles. Obstet Gynecol 92:535-545
30. Plans- Rubió P (2004) Critical prevalence of antibodies minimizing vaccination costs for hepatitis A, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia (Spain). Vaccine 22:4002-4013
31. Plans P, Espuñes J, Plasencia A, Salleras L (2007) Prevalence of varicella-zoster antibodies in pregnant women in Catalonia (Spain). Rationale for varicella vaccination of women childbearing age. Br J Obstet Gynaecol 114:122-127